(Q34476956)

2 August 2017

1 reference

title

Antiangiogenesis therapy. Current and future agents (English)

1 reference

2 August 2017

Kieran MW

1

1 reference

2 August 2017

Billett A

series ordinal

2

1 reference

2 August 2017

publication date

1 October 2001

1 reference

Hematology / Oncology Clinics of North America

2 August 2017

published in

1 reference

2 August 2017

volume

15

1 reference

2 August 2017

issue

5

1 reference

2 August 2017

page(s)

835-51, viii

1 reference

Squalamine, a novel cationic steroid, specifically inhibits the brush-border Na+/H+ exchanger isoform NHE3.

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Response of recurrent medulloblastoma to low-dose oral etoposide

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

The Angiogenesis Inhibitor, Endostatin, Does Not Affect Murine Cutaneous Wound Healing

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Is angiogenesis inhibition the Holy Grail of cancer therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

The hemostatic system as a regulator of angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Tumor angiogenesis--new drugs on the block

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Mechanisms of angiogenesis and arteriogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Angiogenesis in cancer and other diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Clinical strategy for the development of angiogenesis inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Clinical targets for anti-metastasis therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

New paradigms for the treatment of cancer: the role of anti-angiogenesis agents

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Thalidomide is an inhibitor of angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

The angiopoietins: Yin and Yang in angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Mechanisms of tumor-associated edema: a review.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Vascular attack as a therapeutic strategy for cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Tumor angiogenesis and endothelial cell modulatory factors.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Preclinical and clinical studies of MMP inhibitors in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Clinical applications of angiogenic growth factors and their inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Tumor angiogenesis: therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Self-regulation of growth in three dimensions

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Isolation of a tumor factor responsible for angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Prognostic value of vascular endothelial growth factor in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Tumor dormancy in vivo by prevention of neovascularization

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Target molecules for anti-angiogenic therapy: from basic research to clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Small molecule inhibitors of tumor-promoted angiogenesis, including protein tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

New paradigms of signaling in the vasculature: ephrins and metalloproteases

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

The matrix metalloproteinases and their inhibitors in the treatment of pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Matrix metalloproteinases and their inhibitors in tumour growth and invasion

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Tumor angiogenesis: past, present and the near future

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Anticancer drug targets: approaching angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Angiogenesis inhibitor TNP-470 inhibits murine cutaneous wound healing

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Activity of thalidomide in AIDS-related Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

COX-2 inhibitors. A new class of antiangiogenic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Tumour micrometastases: the influence of angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

VEGF receptor signaling in tumor angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Angiostatin induces and sustains dormancy of human primary tumors in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Endostatin: an endogenous inhibitor of angiogenesis and tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Antiangiogenic activity of the cleaved conformation of the serpin antithrombin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Reciprocal paracrine interactions between tumour cells and endothelial cells: the 'angiogenesis progression' hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Models for studying angiogenesis in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Angiogenesis: how a tumor adapts to hypoxia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

1 reference

7 January 2021

Marimastat in patients with advanced pancreatic cancer: a dose-finding study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Antiangiogenic strategies and agents in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Innovative therapies for pediatric brain tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Heparin Affinity: Purification of a Tumor-Derived Capillary Endothelial Cell Growth Factor

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Marimastat (BB2516): current status of development

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Vascular endothelial growth factor receptor-3

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Clinical trials of antiangiogenic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Soluble E-selectin in cancer patients as a marker of the therapeutic efficacy of CM101, a tumor-inhibiting anti-neovascularization agent, evaluated in phase I clinical trail

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Vasculogenesis, angiogenesis, and growth factors: ephrins enter the fray at the border

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Vascular-specific growth factors and blood vessel formation

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Matrix metalloproteinase inhibitors: applications in oncology.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Angiogenesis and tumor metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

Biological parameters for the choice of antiangiogenic therapy and efficacy monitoring.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970254-9

7 January 2021

10.1016/S0889-8588(05)70254-9

Identifiers

DOI

1 reference

2 August 2017

1 reference